Literature DB >> 9158794

Testing the efficacy of a molecular surveillance network: methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) genotypes in six hospitals in the metropolitan New York City area. The BARG Initiative Pilot Study Group. Bacterial Antibiotic Resistance Group.

H de Lencastre1, E P Severina, R B Roberts, B N Kreiswirth, A Tomasz.   

Abstract

Molecular fingerprinting techniques are rapidly becoming indispensable tools for hospital epidemiology. On the other hand, the relative complexity and unfamiliarity of these techniques to most hospital diagnostic laboratories limit their usefulness. In an attempt to provide a solution for this dilemma, we tested the feasibility and efficacy of a cooperative venture in which molecular typing of isolates recovered from patients in six hospitals was performed at two microbiology research laboratories with expertise in these techniques. In a small preliminary study, 30 methicillin-resistant Staphylococcus aureus (MRSA) and 30 vancomycin-resistant Enterococcus faecium (VREF) isolates were collected over a 3-week period from six hospitals in the metropolitan New York area and transported to the Laboratory of Microbiology at The Rockefeller University during the summer months of 1994. Nineteen of the 27 confirmed MRSA isolates were closely related strains carrying the same mecA and the same Tn554 polymorphs in a pulsed-field gel electrophoresis (PFGE) background represented by closely related subtypes of a single pattern, indicating the wide distribution of this MRSA clone among the participating hospitals. Typing of the same 27 MRSA isolates was also performed at the Tuberculosis Center of the Public Health Research Institute and identical results were obtained. The 29 confirmed VREF isolates were highly heterogeneous and belonged to as many as 23 distinct clonal types as defined by PFGE patterns and probing with vanA. Characterization of the 60 isolates by these methods was completed in one month of full-time effort by a single experienced laboratory assistant guided by a doctoral-level expert in molecular fingerprinting techniques. The collection of samples for both MRSA and VREF was not intended to address epidemiological questions but to determine the feasibility of a multicenter study. On the basis of our preliminary findings we are encouraged that a larger cooperative effort is possible and with the correct sampling method we believe that epidemiological and surveillance studies could be accomplished that would provide a tracking system to assist hospitals, clinics, and chronic care facilities in controlling the spread of multidrug-resistant pathogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9158794     DOI: 10.1089/mdr.1996.2.343

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  21 in total

1.  Methicillin-resistant Staphylococcus aureus clonal types in the Czech Republic.

Authors:  O Melter; I Santos Sanches; J Schindler; M Aires de Sousa; R Mato; V Kovárova; H Zemlicková; H de Lencastre
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Genetic organization of the downstream region of the mecA element in methicillin-resistant Staphylococcus aureus isolates carrying different polymorphisms of this region.

Authors:  D C Oliveira; S W Wu; H de Lencastre
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Characterization of isolates of methicillin-resistant Staphylococcus aureus from Hong Kong by phage typing, pulsed-field gel electrophoresis, and fluorescent amplified-fragment length polymorphism analysis.

Authors:  M Ip; D J Lyon; F Chio; M C Enright; A F Cheng
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Genotyping of methicillin-resistant Staphylococcus aureus by assaying for the presence of variable elements associated with mecA.

Authors:  Flavia Huygens; Graeme R Nimmo; Jacqueline Schooneveldt; Wendy J Munckhof; Philip M Giffard
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

5.  Contemporary methicillin-resistant Staphylococcus aureus clones in Hong Kong.

Authors:  Margaret Ip; R W H Yung; T K Ng; W K Luk; Cindy Tse; Philip Hung; Mark Enright; Donald J Lyon
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Clonal structure of Enterococcus faecalis isolated from Polish hospitals: characterization of epidemic clones.

Authors:  Magdalena Kawalec; Zbigniew Pietras; Emilia Daniłowicz; Aleksandra Jakubczak; Marek Gniadkowski; Waleria Hryniewicz; Rob J L Willems
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

7.  Outbreak of vancomycin-resistant Enterococcus faecium of the phenotype VanB in a hospital in Warsaw, Poland: probable transmission of the resistance determinants into an endemic vancomycin-susceptible strain.

Authors:  M Kawalec; M Gniadkowski; M Zaleska; T Ozorowski; L Konopka; W Hryniewicz
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

8.  Clonal distribution of methicillin-resistant Staphylococcus aureus in Poland.

Authors:  T Leski; D Oliveira; K Trzcinski; I S Sanches; M Aires de Sousa; W Hryniewicz; H de Lencastre
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

9.  Vancomycin-resistant Enterococcus faecium strain carrying the vanB2 gene variant in a Polish hospital.

Authors:  M Kawalec; M Gniadkowski; U Zielińska; W Kłos; W Hryniewicz
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

10.  A new local variant (ST764) of the globally disseminated ST5 lineage of hospital-associated methicillin-resistant Staphylococcus aureus (MRSA) carrying the virulence determinants of community-associated MRSA.

Authors:  Tomomi Takano; Wei-Chun Hung; Michiko Shibuya; Wataru Higuchi; Yasuhisa Iwao; Akihito Nishiyama; Ivan Reva; Olga E Khokhlova; Shizuka Yabe; Kyoko Ozaki; Misao Takano; Tatsuo Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.